kmt2a  (ATCC)

Journal: bioRxiv

Article Title: Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

doi: 10.1101/2025.07.08.661805

Figure Lengend Snippet: A) Smarca4 expressions in different murine hardy B fractions – ‘CLP’: Common lymphoid progenitor, ‘Fr. A’: Pre-Pro B, ‘Fr. B’: Early Pro B, ‘Fr. C’: Late Pro B / Large Pre-B, ‘Fr. D’: Small Pre-B, ‘Fr. E’: Immature B, and ‘Fr. F’: Mature B cells (GSE38463). B) Expression of Smarca4 in different murine B developmental stages and lymphoma models (GSE26408). C) SMARCA4 expressions in B-ALL populations compared to T-ALL, CD19+, and CD34+ populations (GSE33315). D) SMARCA4 expressions in different subtypes of B-ALL populations (GSE11877). E) Western blot analysis of BRG1, BRM, and β-actin in four KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and two Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines. F) Mutational frequencies of different oncogenes in B-ALL patient populations from the COG study P9906 (GSE11877). G) Dependency analysis of SMARCA4 via the Cancer Dependency MAP website. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by One-way Anova Dunnett’s multiple comparison test.

Article Snippet: Human KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines listed in Supplementary Table 2 , were obtained from the DSMZ biorepository (Braunschweig, Germany) validated by short tandem repeat (STR) analysis, and confirmed to be Mycoplasma-free every six months - .

Techniques: Expressing, Western Blot, Comparison

Journal: bioRxiv

Article Title: Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

doi: 10.1101/2025.07.08.661805

Figure Lengend Snippet: Kaplan-Meier analysis of the overall survival of all B-ALL (A) , Ph-like B-ALL (B) , and KMT2A -R B-ALL (C) patients from the COG study P9906 with high vs low SMARCA4 mRNA expression (GSE11877). D) Ph-like (red; MUTZ5 and MHH-CALL4) and KMT2A-R B-ALL cell lines (blue; HB11;19 and KOPN8) were treated with increasing concentrations of BRM014 (left) or FHD-286 (right). Viability/cell proliferation was determined via an XTT assay after 72 hours. E) GSEA enrichment plots of Ph-like (MUTZ5 and MHH-CALL4) and KMT2A-R B-ALL cell lines (HB11;19 and KOPN8) after 24 hours of treatment either with control or 100 nM FHD-286. “NES” refers to the Normalized enrichment score (GSE297161). F) RT-PCR was performed to determine the gene expression levels of the indicated genes in Ph-like (MUTZ5 and MHH-CALL4) and KMT2A- R B-ALL cell lines (HB11;19 and KOPN8) after 24 hours of treatment either with control or 100 nM FHD-286. ACTB (Beta Actin) was used as a reference gene to calculate expression levels. Significance was calculated via a log-rank test in Prism (A-C) . Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Two-way Anova Sidak’s multiple comparison test (F) or two-sided Log-rank (Mantel-Cox) test (A-C) .

Article Snippet: Human KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines listed in Supplementary Table 2 , were obtained from the DSMZ biorepository (Braunschweig, Germany) validated by short tandem repeat (STR) analysis, and confirmed to be Mycoplasma-free every six months - .

Techniques: Expressing, XTT Assay, Control, Reverse Transcription Polymerase Chain Reaction, Gene Expression, Comparison

Journal: bioRxiv

Article Title: Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

doi: 10.1101/2025.07.08.661805

Figure Lengend Snippet: A) Cell cycle analysis of the Ph-like (MUTZ5 and MHH-CALL4) and KMT2A- R B-ALL cell lines (HB11;19 and KOPN8) after treatment with 100 nM BRM014 or FHD-286 for 72h. On the left are representative examples of the flow cytometric analysis (n=3), and on the right is the summary of all three experiments. B) Cell viability and apoptosis were tested in control- and BRG1/BRM inhibitor-treated (BRM014 or FHD-286; 100 nM; 72h) Ph-like (MHH-CALL4) and KMT2A -R (SEM and RS4;11) B-ALL cell lines. On the left are representative examples of the flow cytometric analysis (n=3) and on the right is the summary of all three experiments. Data are represented as individual values with mean ± SEM bars. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Two-way Anova Dunnett’s multiple comparison test.

Article Snippet: Human KMT2A -R (SEM, HB11;19, RS4;11, KOPN8) and Ph-like (MUTZ5, MHH-CALL4) B-ALL cell lines listed in Supplementary Table 2 , were obtained from the DSMZ biorepository (Braunschweig, Germany) validated by short tandem repeat (STR) analysis, and confirmed to be Mycoplasma-free every six months - .

Techniques: Cell Cycle Assay, Control, Comparison